Mouth Ulcers - Pipeline Review, Q2 2011

Summary

Company’s, Mouth Ulcers - Pipeline Review, Q2 2011, provides an overview of the Mouth Ulcers therapeutic pipeline. This report provides information on the therapeutic development for Mouth Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mouth Ulcers. Mouth Ulcers - Pipeline Review, Q2 2011 is built using data and information sourced from Company’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Company’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mouth Ulcers.
- A review of the Mouth Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mouth Ulcers pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mouth Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mouth Ulcers pipeline depth and focus of Mouth Ulcers therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
Company Report Coverage 5
Mouth Ulcers Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mouth Ulcers 7
Mouth Ulcers Therapeutics under Development by Companies 9
Mouth Ulcers Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Mouth Ulcers Therapeutics - Products under Development by Companies 14
Mouth Ulcers Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Mouth Ulcers Therapeutics Development 16
Amarillo Biosciences, Inc. 16
Ahn-Gook Pharmaceutical Co., Ltd. 16
Mouth Ulcers - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Interferon Alpha - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Enbrel - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AG SPT201 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Penicillin G Potassium - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Chamomilla Tincture Mouthwash - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 29
Contact Us 29
Disclaimer 29

List of Tables

Number of Products Under Development for Mouth Ulcers, Q2 2011 7
Products under Development for Mouth Ulcers – Comparative Analysis, Q2 2011 8
Number of Products under Development by Companies, Q2 2011 9
Number of Products under Investigation by Universities/Institutes, Q2 2011 10
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 11
Comparative Analysis by Early Clinical Stage Development, Q2 2011 12
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 13
Products under Development by Companies, Q2 2011 14
Products under Investigation by Universities/Institutes, Q2 2011 15
Amarillo Biosciences, Inc., 2011 16
Ahn-Gook Pharmaceutical Co., Ltd., 2011 16
Assessment by Monotherapy Products, Q2 2011 17
Assessment by Stage and Route of Administration, Q2 2011 19
Assessment by Molecule Type, Q2 2011 21

List of Figures

Number of Products under Development for Mouth Ulcers, Q2 2011 7
Products under Development for Mouth Ulcers – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Products under Investigation by Universities/Institutes, Q2 2011 10
Mid Clinical Stage Products, Q2 2011 11
Early Clinical Stage Products, Q2 2011 12
Pre-Clinical Stage Products, Q2 2011 13
Assessment by Monotherapy Products, Q2 2011 17
Assessment by Route of Administration, Q2 2011 18
Assessment by Stage and Route of Administration, Q2 2011 19
Assessment by Molecule Type, Q2 2011 20
Assessment by Stage and Molecule Type, Q2 2011 21